Metastatic Ovarian Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Metastatic Ovarian Cancer - Pipeline Review, H1 2016', provides an overview of the Metastatic Ovarian Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Metastatic Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Ovarian Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer - The report reviews pipeline therapeutics for Metastatic Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Metastatic Ovarian Cancer therapeutics and enlists all their major and minor projects - The report assesses Metastatic Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Metastatic Ovarian Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Metastatic Ovarian Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Metastatic Ovarian Cancer Overview 8 Therapeutics Development 9 Pipeline Products for Metastatic Ovarian Cancer - Overview 9 Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis 10 Metastatic Ovarian Cancer - Therapeutics under Development by Companies 11 Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 12 Metastatic Ovarian Cancer - Pipeline Products Glance 13 Clinical Stage Products 13 Early Stage Products 14 Metastatic Ovarian Cancer - Products under Development by Companies 15 Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes 16 Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development 17 Cellceutix Corporation 17 Eisai Co., Ltd. 18 Eli Lilly and Company 19 F. Hoffmann-La Roche Ltd. 20 Immune Design Corp. 21 Millennium Pharmaceuticals, Inc. 22 MolMed S.p.A. 23 Natco Pharma Limited 24 Northwest Biotherapeutics, Inc. 25 Sumitomo Dainippon Pharma Co., Ltd. 26 VG Life Sciences, Inc. 27 Metastatic Ovarian Cancer - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Combination Products 29 Assessment by Target 30 Assessment by Mechanism of Action 32 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Drug Profiles 38 CMB-305 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 DCVax-Direct - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 E-7449 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 emactuzumab - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 G-305 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 hydroxychloroquine + sorafenib tosylate - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 KM-3174 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 LV-305 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 LY-2780301 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 NGR-hTNF - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 NRCAN-019 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 orteronel - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 OS-2966 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 SM-276001 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Vaccine for Oncology - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Metastatic Ovarian Cancer - Recent Pipeline Updates 64 Metastatic Ovarian Cancer - Dormant Projects 83 Metastatic Ovarian Cancer - Discontinued Products 84 Metastatic Ovarian Cancer - Product Development Milestones 85 Featured News & Press Releases 85 Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent 85 Appendix 86 Methodology 86 Coverage 86 Secondary Research 86 Primary Research 86 Expert Panel Validation 86 Contact Us 86 Disclaimer 87
List of Tables
Number of Products under Development for Metastatic Ovarian Cancer, H1 2016 9 Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Metastatic Ovarian Cancer - Pipeline by Cellceutix Corporation, H1 2016 17 Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H1 2016 18 Metastatic Ovarian Cancer - Pipeline by Eli Lilly and Company, H1 2016 19 Metastatic Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 20 Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H1 2016 21 Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 22 Metastatic Ovarian Cancer - Pipeline by MolMed S.p.A., H1 2016 23 Metastatic Ovarian Cancer - Pipeline by Natco Pharma Limited, H1 2016 24 Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016 25 Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 26 Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H1 2016 27 Assessment by Monotherapy Products, H1 2016 28 Assessment by Combination Products, H1 2016 29 Number of Products by Stage and Target, H1 2016 31 Number of Products by Stage and Mechanism of Action, H1 2016 33 Number of Products by Stage and Route of Administration, H1 2016 35 Number of Products by Stage and Molecule Type, H1 2016 37 Metastatic Ovarian Cancer Therapeutics - Recent Pipeline Updates, H1 2016 64 Metastatic Ovarian Cancer - Dormant Projects, H1 2016 83 Metastatic Ovarian Cancer - Discontinued Products, H1 2016 84
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.